conclusions: This meta-analysis showed a 2-fold risk of arterial disease for patients with PCOS relative to women without PCOS. BMI adjustment did not affect this finding, suggesting the increased risk for cardiovascular events in PCOS is not completely related to a higher BMI in patients with PCOS.
Introduction
Since the publication by Stein and Leventhal (1935) on polycystic ovary syndrome (PCOS), one biological definition [World Health Organization (WHO) II anovulation; WHO II; WHO (1973) ] and three consensus definitions have been published on PCOS: National Institutes of Health (NIH) in 1990 (Zawadski, 1992) , Rotterdam in 2003 (R'dam; Rotterdam, 2004) and Androgen-excess PCOS in 2006 (AE; Azziz et al., 2009) . In the NIH definition the symptoms hyperandrogenism and anovulation were considered as important features of PCOS. The Rotterdam consensus work group added polycystic ovary morphology to these two criteria, whereas the Androgen-excess PCOS criteria were the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries) and the exclusion of related disorders.
Apart from anovulation, increased BMI is a common feature in women with PCOS, with a prevalence of 30-70% (Zawadski, 1992; Azziz et al., 2004; Ehrmann, 2005; Broekmans et al., 2006; Vrbikova and Hainer, 2009) . Since the 90s of the last century an association between PCOS and cardiovascular disease, predominantly arterial disease, has been recognized. The American Society for Reproductive Medicine (ASRM) Practice Committee associated PCOS with an increased risk for cardiovascular diseases (ASRM, 2008) . In a search in PubMed (14 September 2010), 481 hits were retrieved by inserting 'PCOS' and the MeSH term 'cardiovascular disease', and 197 of these hits were reviews. As PCOS is associated with obesity, it is still under debate whether in PCOS the possible increased risk for cardiovascular events (such as myocardial infarction or stroke), is merely related to obesity. Or does PCOS per se contribute to this increased risk, independent of obesity? Therefore, we examined in this systematic review whether patients with PCOS, defined according to the currently used WHO (WHO, 1973) , NIH (Zawadski, 1992) , Rotterdam (Rotterdam, 2004) and AE PCOS (Azziz et al., 2009 ) criteria, have a higher risk of fatal or nonfatal coronary heart disease (CHD) or stroke relative to ovulatory women without PCOS. Further, we assessed whether obesity among patients with PCOS might explain a possible higher risk of CHD or stroke.
Methods

Identification of trials and eligibility criteria
Controlled studies comparing women with PCOS to women without PCOS were considered for eligibility. We selected reports with categorical data on any of the following outcomes: incident CHD and/or stroke (non-fatal or fatal). Studies without a control group or that did not distinguish women with or without PCOS were not included.
Comparison of PCOS to non-PCOS can only be assessed in observational studies, thereby restricting this meta-analysis to nonrandomized studies.
For study inclusion, PCOS should have been defined according to the WHO (WHO, 1973) , NIH (Zawadski, 1992) , Rotterdam (Rotterdam, 2004) or AE (Azziz et al., 2009) criteria and the control group should be PCOS-free. For the definition of obesity and waist circumference associated with health risk, we used the criteria of the American Medical Association (2010) and WHO (2006) for women: obesity (.30 kg/m 2 ) and waist circumference .88 cm (Whitlock et al., 2009 ).
The definition of CHD and stroke was based on the criteria used by the various authors. Relevant studies were identified from the Cochrane Central Register of Controlled Trials (CENTRAL) using the keyword PCOS and cardiovascular disease. The National Center for Biotechnology Information Pubmed database was searched for articles published before January 2010 using any combination of the terms 'PCOS, polycystic ovarian syndrome, adipositas, obesity, myocardial infarction, stroke, cerebrovascular accident, cardiac disease, arterial occlusive disease, heart disease, cardiac disease'. The EMBASE, CINAHL, POPLINE and LILACS databases were searched in a similar fashion for additional articles. The detailed search strategy is displayed in Appendix 1. Review articles were cross-referenced with the results of the expanded search. Manual searches were performed of the reference lists of selected articles. The search was not limited by language or publication status. Data extraction was independently performed by three investigators (P.G., S.W.M.D., F.M.H.). Disagreement was resolved by consensus.
Quality assessment
The quality of the included studies was assessed according to the NewcastleOttawa Scale (Higgins and Green, 2009 ), a validated scale for meta-analysis of observational studies. We scored (max. nine points) the following items important for risk of bias assessment in nonrandomized cohort studies: representativeness of the exposed cohort; adequate selection of controls; adequate definition of the outcome (CHD/stroke); adequacy of follow-up; comparability of exposed and nonexposed women (two points). Low methodological quality was not an exclusion criterion.
Data analysis
The primary outcome of the meta-analysis was the pooled risk ratio for CHD or stroke or mortality related to CHD or stroke for women with PCOS compared with women without PCOS. In a second analysis we calculated the BMI-adjusted pooled risk ratio. Studies reporting risk ratios as well as studies reporting rate ratios were eligible. For all studies the risk ratio and its accompanying Standard error were extracted. On the basis of the expected heterogeneity of the included studies we performed a random effects model by default. Heterogeneity was calculated with the I 2 statistics. All analyses were performed with STATA 10.0, StataCorp LP, TX, USA.
Results
Literature search and study characteristics
The initial search (Fig. 1 ) yielded 1340 hits, 332 of which were duplicates. A total of 996 articles were not relevant for the research question, leaving 12 articles for detailed evaluation. In the reference list of those 12 publications, two additional articles were identified, providing 14 articles for the current review. Nine studies were excluded for the following reasons:
(i) surrogate endpoints for CHD (Dahlgren et al., 1992a, b; Birdsall and Farquhar, 1997; Elting et al., 2001; Moini and Eslami, 2009 ), (ii) controls were mothers of daughters with PCOS (Cheang et al., 2008) , (iii) PCOS definition not compatible with one of the four PCOS definitions of our study (WHO II, NIH, R'dam, AE) (Krentz et al., 2007) and (iv) double publication (Pierpoint et al., 1998; Wild et al., 2000a) .
Finally, a total of five studies were included (Cibula et al., 2000; Wild et al., 2000b; Solomon et al., 2002; Lunde and Tanbo, 2007; Shaw et al., 2008;  Table I for detailed information).
All five studies examined a cohort. All five studies used the WHO II anovulation criterion, three the NIH (Cibula et al., 2000; Lunde and Tanbo, 2007; Shaw et al., 2008) , four the R'dam (Shaw et al., 2008; Wild et al., 2000b; Cibula et al., 2000; Lunde and Tanbo, 2007) and four the AE definition (Cibula et al., 2000; Wild et al., 2000b; Lunde and Tanbo, 2007; Shaw et al., 2008) . Race was mentioned by Cibula et al. (2000) 'all Caucasians', by Solomon et al. (2002) '98% Caucasians' and Wild et al., (2000b) '99% white etnic origin'. Shaw et al. (2008) , Solomon et al. (2002) and Wild et al. (2000b) presented data of fatal cases due to acute myocardial infarction (AMI) and stroke. Lunde and Tanbo (2007) used hard clinical outcome of AMI, whereas Solomon et al. (2002) included 17% probable cases of non-fatal acute myocardial infarction/stroke in their analyses and Cibula et al. (2000) used no hard clinical outcome of non-fatal CHD ('chest pain evaluated as definite or possible angina, a history of definite or possible myocardial infarction, a history of transluminal percutaneous coronary angioplasty or coronary artery bypass grafting'). None of the five studies presented separate data for obesity (BMI and/or waist circumference) in the cases and controls. Four studies provided risk ratios, one study a rate ratio. Table II shows the assessment of methodological quality according the Newcastle -Ottawa Scale (Higgins and Green, 2009) . One study scored seven out of nine points (Shaw et al., 2008) and one study scored six points (Solomon et al., 2002) , indicating high-quality. Three studies scored four points or less (Cibula et al., 2000; Wild et al., 2000b; Lunde and Tanbo, 2007) , indicating low quality.
Meta-analysis
The relative risk for cardiovascular events ranged from 0.92 to 4.24. Four of five studies showed individually a significant increased risk for women with PCOS. The pooled relative risk from a random effects model was 2.02 (95% confidence interval 1.47, 2.76), showing a 2-fold increased risk for CHD/stroke in women with PCOS. The I 2 showed moderate heterogeneity (42%) (Fig. 2) . Two studies provided BMI-adjusted risk estimates (Wild et al., 2000b; Solomon et al., 2002;  Fig. 3 ). The pooled relative risk adjusted for BMI was 1.55 (95% confidence interval 1.27, 1.89). In both analyses most weight came from the Solomon study (Solomon et al., 2002) that scored six out of nine points with the Newcastle -Ottawa Scale.
Discussion
The present meta-analysis was performed to assess the risk for cardiovascular events in PCOS. The five included studies showed heterogeneity in design, definitions and quality. A significant 2-fold risk of CHD and stroke for patients with PCOS relative to women without PCOS was found. Moreover, the risk was still increased by 55% in the studies that adjusted for BMI. This shows that increased BMI is not the sole cause of the increased cardiovascular risk in women with PCOS. The largest weight in the meta-analysis was provided by a high-quality study. In a systematic review on impaired glucose tolerance, type 2 diabetes and metabolic syndrome in PCOS, Moran et al. (2010) recently found that women with PCOS had increased prevalence of impaired glucose tolerance, type 2 diabetes in both BMI and non-BMI-matched studies. This meta-analysis has several limitations. First, the definitions of PCOS used were not identical for all studies. Whereas anovulation is a characteristic of all definitions, it could not be estimated from the data whether the specific features of the other PCOS definitions (NIH, Rotterdam and AE) compared with the WHO anovulation have an effect on this risk. Second, hard clinical outcome data were not always used and separate data for coronary disease and stroke were not available in all five studies.
What are the implications of the results? We have shown that PCOS is associated with an increased cardiovascular risk. However, we are far from causality as formulated by Hill (1965) and various important questions remain to be investigated. Although increased BMI was not the sole cause of the increased risk for cardiovascular events, the role of BMI should be investigated in more detail in prospective studies. It is an open question whether the other distinguishing features of PCOS, such as hyperandrogenism, are causing the risk excess (Jovanovic et al., 2010) . A possible interference of infertility and of fertility treatments for patients with anovulation-the most explicit feature of ovarian dysfunction-on their arterial health might be involved.
Implications for practice
Our study showed that PCOS should be considered as a risk factor for cardiovascular disease; importantly, this risk is partially independent of BMI. Nevertheless, weight reduction remains an important aim of treatment in overweight patients with PCOS. 
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